KAS
SUPN icon

Kestra Advisory Services’s Supernus Pharmaceuticals SUPN Stock Holding History

Kestra Advisory Services’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$224K Sell
4,332
-1,124
-21% -$57.2K ﹤0.01% 2861
2025
Q4 		$271K Sell
5,456
-2,018
-27% -$98.1K ﹤0.01% 2624
2025
Q3 		$357K Sell
7,474
-732
-9% -$29.5K ﹤0.01% 2303
2025
Q2 		$259K Buy
8,206
+30
+0.4% +$961 ﹤0.01% 2466
2025
Q1 		$268K Sell
8,176
-618
-7% -$21.9K ﹤0.01% 2250
2024
Q4 		$318K Buy
+8,794
New +$310K ﹤0.01% 2178

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kestra Advisory Services's SUPN Position: Q1 2026 in Review

Kestra Advisory Services reduced its Supernus Pharmaceuticals (SUPN) stake by 21% in Q1 2026, selling an estimated $57.2K and leaving 4,332 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #2861.

Kestra Advisory Services first reported a position in SUPN in Q4 2024 and has held it in 6 quarters since. The position peaked at $357K in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Kestra Advisory Services held 4,332 shares of Supernus Pharmaceuticals worth $224K as of Q1 2026.
  • Kestra Advisory Services sold 1,124 Supernus Pharmaceuticals shares in Q1 2026, an estimated $57.2K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Kestra Advisory Services's portfolio in Q1 2026, its #2861 holding.
  • Kestra Advisory Services first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Kestra Advisory Services's Supernus Pharmaceuticals position peaked at $357K in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.